European Pharmaceutical Review

AUGUST 16, 2022

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated version of Moderna’s COVID-19 vaccine, Spikevax, that targets two coronavirus variants as a booster. The regulator confirmed that the vaccine meets its standards of safety, quality and effectiveness. 1) and the original 2020 strain.

Vaccines 105

Vaccines Immunization 105

The Checkup by Singlecare

SEPTEMBER 22, 2023

This year, there are new vaccines to help at-risk populations ward off severe sickness, including that caused by RSV. Here’s what you need to know about the new FDA-approved RSV vaccine. But young children, older adults, and individuals with weakened immune systems are at high risk of severe, potentially life-threatening RSV illness.

Vaccines 105

Vaccines Immunization Insurance FDA 105

pharmaphorum

JANUARY 19, 2023

Biotech Vaxxas has announced a partnership agreement with the 2017-established Coalition for Epidemic Preparedness Innovations (CEPI), in order to advance the development of Vaxxas’ needle-free vaccine-patch delivery technology with preclinical testing of an mRNA vaccine patch. The agreement, worth $4.3 The agreement, worth $4.3

Vaccines 105

Vaccines Immunization 105

pharmaphorum

AUGUST 12, 2021

The UK government has started ordering COVID-19 vaccines for a 2022 booster campaign, including a 32 million-dose order for the Pfizer/BioNTech shot, even before third doses for 2021 have been given the go-ahead. The Johnson & Johnson vaccine is also supplied on a no-profit basis. Pricing slammed.

Vaccines 111

Vaccines Immunization 111

European Pharmaceutical Review

DECEMBER 2, 2022

Vaccines Europe has unveiled its first pipeline review of its 15 members companies, with 100 vaccine candidates as of July 2022. . The data indicated 46 percent of the vaccine candidates target infections that do not have an available vaccine. Improve access and convenience to immunisation for adults.

Vaccines 98

Vaccines Immunization 98

European Pharmaceutical Review

NOVEMBER 18, 2022

The World Health Organization (WHO)’s Global Vaccine Market Report 2022 , the first report to examine the impact of COVID-19 on the global vaccine market, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently fighting to access vaccines in demand by wealthier countries.

Vaccines 98

Vaccines Immunization Documentation 98

Pharmaceutical Technology

MAY 2, 2023

4/5 Covid-19 messenger RNA (mRNA) vaccines. The expanded EUAs state that these current bivalent vaccines are now to be used for all primary and booster doses administered to individuals ages six months of age and older. 1 vaccines by both companies were revoked by the FDA in August 2022, after the BA.5

Vaccines 21

Vaccines FDA Immunization 21

PharmTech

JUNE 10, 2025

s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. Washington, DC, USA - June 24, 2022: The symbol of the U.S. Kennedy Jr.

Vaccines 85

Vaccines Dosage Packaging Immunization 85

Hospital Pharmacy Europe

JANUARY 25, 2023

The Joint Committee on Vaccination and Immunisation (JCVI) has advised offering Covid booster vaccinations in spring and autumn 2023 for patients deemed to be at high risk. That is why we have advised planning for further booster vaccines for persons at higher risk of serious illness through an autumn booster programme later this year.

Vaccines 98

Vaccines Immunization Hospitals 98

European Pharmaceutical Review

AUGUST 30, 2022

Pfizer has announced positive top-line data from a Phase III clinical trial (NCT05035212) investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older. In more severe disease with primary endpoint of LRTI-RSV defined by three or more symptoms, vaccine efficacy of 85.7

Vaccines 98

Vaccines FDA Immunization 98

European Pharmaceutical Review

AUGUST 22, 2022

THE GLOBAL outbreak of the COVID-19 pandemic triggered an urgent need to protect people’s lives and livelihoods and the healthcare community recognised quite early that vaccines were the best solution to this crisis. Novel biotechnology platforms for vaccine development.

Vaccines 98

Vaccines Immunization 98

European Pharmaceutical Review

AUGUST 26, 2022

Moderna has filed patent infringement lawsuits alleging that Pfizer and BioNTech’s COVID-19 vaccine Comirnaty ® infringes patents Moderna filed between 2010 and 2016 covering its foundational messenger RNA (mRNA) technology. Pfizer and BioNTech copied this technology, without Moderna’s permission, to make Comirnaty,” said Moderna.

Vaccines 98

Vaccines Immunization 98

pharmaphorum

SEPTEMBER 15, 2020

billion) order for up to 190 million doses of a coronavirus vaccine in development at French company Valneva. The new deal firms up an earlier agreement in principle with the UK in July that covered up to 100 million doses of VLA2001 , a purified inactivated SARS-CoV-2 vaccine that is expected to require a two-dose vaccination regimen.

Vaccines 80

Vaccines Immunization 80

Pharmaceutical Technology

JANUARY 19, 2023

The Korean Ministry of Food and Drug Safety (KMFDS) has granted expanded approval to Novavax partner SK bioscience for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), for use as a booster dose in adults aged 18 and above. Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain.

Vaccines 59

Vaccines Immunization 59

Roots Analysis

MARCH 16, 2023

It is worth noting that several companies have begun to develop mRNA-based cancer immunotherapies and vaccines for infectious diseases. mRNA Therapeutics and Vaccines Delivery Routes Efficient delivery of both therapeutic and vaccine candidates plays a key role in ensuring the effective expression and presentation of antigens.

Vaccines 52

Vaccines Immunization 52

European Pharmaceutical Review

NOVEMBER 10, 2023

The US Food and Drug Administration (FDA) has approved Valneva SE’s IXCHIQ ® , the first chikungunya vaccine to be authorised in the world. The single-dose, live-attenuated vaccine is indicated for preventing chikungunya virus disease in individuals over 18 years old who are at increased risk of contracting the virus.

Vaccines 52

Vaccines Adverse Reactions FDA Immunization 52

pharmaphorum

AUGUST 26, 2022

The rivalry between Moderna and Pfizer/BioNTech in commercialising their COVID-19 vaccines has now spilled over into the courts, in the form of a patent infringement lawsuit. ” There’s no world yet on whether a counter-suit may be in the offing. .” Lawsuits sprouting like mushrooms.

Vaccines 59

Vaccines Immunization 59

Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20.

Vaccines 64

Vaccines FDA Immunization 64

Pharmaceutical Technology

AUGUST 26, 2022

Amid a shortage of monkeypox vaccine doses, the WHO and FDA have declared public health emergencies, and the FDA has granted its first Emergency Use Authorization (EUA) to a monkeypox vaccine and opened the door for more. On the same day, the FDA granted a EUA to Bavarian Nordic’s (Copenhagen, Denmark) Jynneos vaccine.

Vaccines 52

Vaccines FDA Immunization 52

Pharmaceutical Technology

JUNE 8, 2023

Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as a boost against Covid-19 (CORAL-BOOST). These results were first reported by Gritstone in October 2022. According to GlobalData , there are over 800 Covid-19 vaccines in the pipeline, 42.6%

Vaccines 52

Vaccines Immunization Communication 52

pharmaphorum

MARCH 17, 2022

Alnylam claims it is owed a slice of the massive revenues booked by Pfizer and Moderna for their mRNA-based COVID-19 vaccines, because they are both infringing patents its holds on a delivery technology. Pfizer made $36 billion in sales from Comirnaty last year, and is expecting to shift another $32 billion-worth in 2022.

Vaccines 52

Vaccines Immunization 52

pharmaphorum

MAY 31, 2022

billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer’s Prevnar franchise. billion in the previous year, but revenues bounced back in the first quarter of 2022, rising 59% to $1.57 GlaxoSmithKline has agreed a $3.3

Vaccines 52

Vaccines Immunization FDA 52

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.

Vaccines 59

Vaccines Immunization Medical Schools FDA 59

pharmaphorum

AUGUST 16, 2022

The UK’s Joint Committee on Vaccinations and Immunisations (JCVI) has said that Moderna’s bivalent COVID-19 vaccine should be used for the autumn booster campaign in adults. The UK is the first country to approve use of an Omicron-targeted vaccine. 1 subvariant. More: [link].

Vaccines 59

Vaccines Immunization 59

Pharmacy Times

JUNE 12, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Vaccines 65

Vaccines Immunization Compounding Pharmacies FDA 65

The Checkup by Singlecare

MARCH 25, 2025

During the COVID-19 pandemic, broad immunization was key, so the Centers for Disease Control and Prevention (CDC) provided funding for free vaccines. And while COVID-19 vaccines are still typically free for people who have health insurance, Medicare, or Medicaid, uninsured individuals may still need to pay $80$200 and up for it.

Vaccines 52

Vaccines Insurance Immunization Insurance Coverage 52

Pharmacy Times

JUNE 17, 2025

OTC Use Saves Billions From Cost-Effective Products and Encounters Image credit: Amina | stock.adobe.com A 2022 publication purported $167 billion in savings in ancillary health care cost avoidance through the widespread use of OTC products in the United States.

Compounding Pharmacies 132

Compounding Pharmacies Drug Utilization Review Immunization Compounding 132

Drug Topics

JUNE 18, 2025

Following a switch in Sweden’s National Immunization Program (NIP), children in the country reported an increase in pneumococcal hemolytic uremic syndrome (pHUS) from 2009 through 2024. In the US, recommendations are slightly different, with PCV13 being the safest and most effective pneumococcal vaccine for both children and adults.

Immunization 476

Immunization Vaccines Compounding Specialty Pharmacies 476

European Pharmaceutical Review

NOVEMBER 1, 2023

In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens. WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development.

Vaccines 115

Vaccines Immunization 115

European Pharmaceutical Review

AUGUST 3, 2022

The COVID-19 pandemic has demonstrated the need for an improved vaccine approach to temper the serious threat of constantly mutating viruses, such as influenza and coronaviruses, on global health. Current vaccine strategies and their limitations. The adaptive immune response to a natural infection.

Vaccines 95

Vaccines Immunization 95

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology.

Vaccines 97

Vaccines Immunization 97

European Pharmaceutical Review

FEBRUARY 14, 2023

Recently there have been several key advances in the clinical development of messenger RNA (mRNA) vaccines, including vaccines for RSV and a personalised cancer vaccine. 2 Yet according to a 2022 report by GlobalData, it is difficult to achieve high quality and highly pure mRNA via scalable manufacturing.

Vaccines 105

Vaccines Immunization FDA 105

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccines 117

Vaccines Immunization 117

Pharmacy Times

JUNE 18, 2025

In 2022, it received approval from the FDA for patients with HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) infection. These processes allowed for lenacapavir to have an expedited review process due to the substantial improvements it could make compared with currently available therapies.

FDA 117

FDA Compounding Pharmacies Immunization Compounding 117

Pharmaceutical Technology

MAY 11, 2023

Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.

Vaccines 138

Vaccines Immunization 138

PharmaShots

MAY 23, 2023

Was ranked the highest among the list of companies developing Cell & Gene therapy, followed by Novartis with a revenue of $50.54B and Spark Therapeutics with a revenue of $49.27B PharmaShots brings an informative report on the Top 20 Cell and Gene Therapy Companies based on the total Revenue generated in the year 2022 Total Revenue: $0.5M

FDA 58

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 58

European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111

Vaccines Communication Immunization Documentation 111